{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/diarrhoea-antibiotic-associated/","result":{"data":{"firstChapter":{"id":"ff00d31e-fff0-5539-893c-63eaae28aa91","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field b50f5465-31b0-4238-b1fb-e60cf45e73ee --><h1>Diarrhoea - antibiotic associated: Summary</h1><!-- end field b50f5465-31b0-4238-b1fb-e60cf45e73ee -->","htmlStringContent":"<!-- begin item 7021a253-163c-44f6-9113-021daffc4dca --><!-- begin field 149c038d-4946-459a-80c7-b0f6a84731fb --><ul><li>Diarrhoea is a common consequence of treatment with antibiotics, occurring in 2–25% of people taking antibiotics, depending on the antibiotic prescribed.</li><li>Around 20% to 30% of cases of antibiotic-associated diarrhoea are due to <em>Clostridium difficile</em>. Antibiotics frequently associated with <em>C. difficile</em> infection include clindamycin, cephalosporins (especially third and fourth generation), fluoroquinolones, and broad-spectrum penicillins. </li><li>Factors that increase the risk of <em>C. difficile </em>infection include increased age, history of <em>C. difficile</em> infection, exposure to other cases, concomitant use of a proton pump inhibitor or other acid-suppressing drug, and underlying morbidity (such as abdominal surgery, chronic renal disease, inflammatory bowel disease, and immunosuppression).</li><li>The complications of <em>C. difficile </em>infection can be severe and include pseudomembranous colitis, toxic megacolon, perforation of the colon, sepsis, and death.</li><li>The severity of symptoms should be assessed and the need for hospital admission considered.</li><li>If infection with <em>C. difficile </em>is suspected, a stool sample should be taken.</li><li>If infection with <em>C. difficile </em>is not suspected or testing for <em>C. difficile</em> is negative:<ul><li>The antibiotic should be stopped, if this is appropriate.</li><li>Fluid loss and symptoms should be managed as for acute gastroenteritis.</li></ul></li><li>If the <em>C. difficile </em>toxin test result is positive:<ul><li>Mild-to-moderate infection is managed with antibiotics (usually oral metronidazole) according to local policy or advice from a microbiologist.</li><li>Risk of a <em>C. difficile </em>outbreak should be assessed — for example, among other elderly residents in a care or nursing home.</li><li>Any antibiotics not being used for treating <em>C. difficile </em>infection should be stopped, if this is appropriate.</li><li>Fluid loss and symptoms should be managed.</li><li>Antimotility drugs (such as loperamide) should be avoided.</li><li>Advice should be given on hygiene measures to minimize the spread of <em>C. difficile</em>.</li></ul></li><li>Diarrhoea due to <em>C. difficile </em>infection should resolve in 1–2 weeks. The person will remain infectious whilst they still have symptoms and they should stay away from work or school until they have been free from diarrhoea for 48 hours.</li></ul><!-- end field 149c038d-4946-459a-80c7-b0f6a84731fb --><!-- end item 7021a253-163c-44f6-9113-021daffc4dca -->","topic":{"id":"e3d5d597-cb8d-5009-95be-96d5f61f622c","topicId":"60505e59-3d44-4100-ba77-670b2dda81a3","topicName":"Diarrhoea - antibiotic associated","slug":"diarrhoea-antibiotic-associated","aliases":[],"chapters":[{"id":"ff00d31e-fff0-5539-893c-63eaae28aa91","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"d4f02cb1-a605-5763-85b8-7e30efe0b52d","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"b4be21a4-fea2-52ee-99b9-6ad9b7f42b37","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"14b5fd2c-0a9a-58b3-af3b-54e8f6c587a3","slug":"changes","fullItemName":"Changes"},{"id":"86cd74d6-6f35-5de4-9031-55397958409b","slug":"update","fullItemName":"Update"}]},{"id":"d9b8d789-d6e6-5a0f-80ef-2853843c67b6","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"93a9787b-a3ca-5bd2-9dd1-e7bd5ebd7e61","slug":"goals","fullItemName":"Goals"},{"id":"712c6134-ba14-5e2a-987b-8d3c06033ee0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"04b62294-302f-5852-90f5-60c1f9593a96","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"98b4954c-4b96-5b7a-9888-99cfd0b2ce3d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f04cf05-c2de-5fb3-9f58-b7e32b7a8604","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d849aa0f-051e-5e61-8d05-6da99fdc60e0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"146be3ba-ef2c-5d7c-a6be-75d743b6cbdb","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"3deeffef-b60e-557b-a9ce-2ca055de0653","slug":"definition","fullItemName":"Definition"},{"id":"788d8348-35a0-5147-b765-a90a068257b9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7804f825-6a78-5c22-89f7-9ecb4f2ac588","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4d2b177e-1c5d-5783-b256-b0b7173e4660","slug":"complications","fullItemName":"Complications"},{"id":"0d3b3c20-ff70-5653-9cb1-750667c15098","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"db6311c9-b63f-5037-89f3-fe2ed41761c7","slug":"management","fullItemName":"Management","subChapters":[{"id":"1ddecd55-2bf4-53db-8594-8c1489126404","slug":"diarrhoea-antibiotic-associated","fullItemName":"Scenario: Diarrhoea - antibiotic associated"}]},{"id":"e0650ec6-ca9b-5cf0-9761-2ffe00571666","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"4f209e3e-56a5-5f47-859e-8b6f0b9b9fe9","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"1a19af07-ea9e-59ac-8ce6-508d4d01e536","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"ecd4dd69-cf4c-507f-9659-b23f2a5b3272","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"b0079d2b-b8c1-59e3-a1c1-f6f2c83a07c5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"919502d7-1740-58a4-8ea5-2feeb47d6e28","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d1844305-0beb-50de-a2de-fbea6a58b880","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"766c971f-c448-56d3-a9d4-2ffded846f90","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d18a1e0-eeb3-5b2f-bd26-e9f231d83c40","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"99309640-cab2-57c4-8bd0-2c05065abd69","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"e3d5d597-cb8d-5009-95be-96d5f61f622c","topicId":"60505e59-3d44-4100-ba77-670b2dda81a3","topicName":"Diarrhoea - antibiotic associated","slug":"diarrhoea-antibiotic-associated","aliases":[],"topicSummary":"Diarrhoea is a common consequence of treatment with antibiotics, occurring in 225% of people taking antibiotics","lastRevised":"Last revised in November 2020","nextPlannedReviewBy":"2024-03-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2024-03","nextPlannedReviewByDisplay":"March 2024","specialities":[{"id":"45db1917-4d65-58d8-af3d-568321e486ed","name":"Drugs and devices","slug":"drugs-devices"},{"id":"e4fd15e3-ef70-523f-843c-5270742f518d","name":"Gastrointestinal","slug":"gastrointestinal"},{"id":"e174a859-759f-5b1d-898e-1a4155645e13","name":"Infections and infestations","slug":"infections-infestations"}],"chapters":[{"id":"ff00d31e-fff0-5539-893c-63eaae28aa91","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"d4f02cb1-a605-5763-85b8-7e30efe0b52d","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"b4be21a4-fea2-52ee-99b9-6ad9b7f42b37","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"14b5fd2c-0a9a-58b3-af3b-54e8f6c587a3","slug":"changes","fullItemName":"Changes"},{"id":"86cd74d6-6f35-5de4-9031-55397958409b","slug":"update","fullItemName":"Update"}]},{"id":"d9b8d789-d6e6-5a0f-80ef-2853843c67b6","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"93a9787b-a3ca-5bd2-9dd1-e7bd5ebd7e61","slug":"goals","fullItemName":"Goals"},{"id":"712c6134-ba14-5e2a-987b-8d3c06033ee0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"04b62294-302f-5852-90f5-60c1f9593a96","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"98b4954c-4b96-5b7a-9888-99cfd0b2ce3d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f04cf05-c2de-5fb3-9f58-b7e32b7a8604","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d849aa0f-051e-5e61-8d05-6da99fdc60e0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"146be3ba-ef2c-5d7c-a6be-75d743b6cbdb","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"3deeffef-b60e-557b-a9ce-2ca055de0653","slug":"definition","fullItemName":"Definition"},{"id":"788d8348-35a0-5147-b765-a90a068257b9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7804f825-6a78-5c22-89f7-9ecb4f2ac588","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4d2b177e-1c5d-5783-b256-b0b7173e4660","slug":"complications","fullItemName":"Complications"},{"id":"0d3b3c20-ff70-5653-9cb1-750667c15098","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"db6311c9-b63f-5037-89f3-fe2ed41761c7","slug":"management","fullItemName":"Management","subChapters":[{"id":"1ddecd55-2bf4-53db-8594-8c1489126404","slug":"diarrhoea-antibiotic-associated","fullItemName":"Scenario: Diarrhoea - antibiotic associated"}]},{"id":"e0650ec6-ca9b-5cf0-9761-2ffe00571666","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"4f209e3e-56a5-5f47-859e-8b6f0b9b9fe9","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"1a19af07-ea9e-59ac-8ce6-508d4d01e536","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"ecd4dd69-cf4c-507f-9659-b23f2a5b3272","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"b0079d2b-b8c1-59e3-a1c1-f6f2c83a07c5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"919502d7-1740-58a4-8ea5-2feeb47d6e28","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d1844305-0beb-50de-a2de-fbea6a58b880","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"766c971f-c448-56d3-a9d4-2ffded846f90","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d18a1e0-eeb3-5b2f-bd26-e9f231d83c40","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"99309640-cab2-57c4-8bd0-2c05065abd69","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"e3d5d597-cb8d-5009-95be-96d5f61f622c"}},"staticQueryHashes":["3666801979"]}